European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia
DOI: 10.1016/j.annonc.2025.01.022
Publication date: February 2025
Publications
Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study
Main author: Luca Bertamini
Publication date: December 2024
Connected Trials:
EMN17
Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma
Main author: Broijl
Publication date: November 2024
Connected Trials:
EMN15
Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial
Main author: Sonneveld
Publication date: November 2024
Connected Trials:
EMN02
Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
Main author: Zamagni
Publication date: November 2024
Connected Trials:
No connected trials
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Main author: Sonneveld
DOI: 10.1056/NEJMoa2312054
Publication date: December 2023
Connected Trials:
EMN17
Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study
Main author: van de Donk
Publication date: November 2023
Connected Trials:
EMN26
Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients
Main author: Gay
Publication date: November 2023
Connected Trials:
EMN24
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial
Main author: Dimopoulos
DOI: https://doi.org/10.1016/S2352-3026(23)00218-1
Publication date: October 2023
Connected Trials:
EMN14
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
Main author: van de Donk
DOI: https://doi.org/10.1016/S1470-2045(23)00405-9
Publication date: September 2023
Connected Trials:
EMN12
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Main author: Terpos
DOI: 10.1038/s41375-023-01920-1
Publication date: June 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Main author: Ludwig
DOI: 10.1016/S1470-2045(23)00159-6
Publication date: June 2023
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project
Main author: D'Agostino
DOI: 10.1200/JCO.21.02614
Publication date: May 2022
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Main author: Ludwig
DOI: https://doi.org/10.1016/S2352-3026(21)00278-7
Publication date: October 2021
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
Main author: Sonneveld
DOI: 10.1200/JCO.21.01045
Publication date: September 2021
Connected Trials:
EMN02
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
Main author: Dimopoulos
DOI: 10.1016/S1470-2045(21)00128-5
Publication date: June 2021
Connected Trials:
EMN14
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: How to distinguish (and manage) Dr. Jekyll and Mr. Hyde
Main author: Musto
DOI: 10.3324/haematol.2021.278519
Publication date: May 2021
Carfilzomib, bendamustine, dexamethasone in patients with advanced multiple myeloma: The EMN09 Phase I/II study of the European Myeloma Network
Main author: Gramatzki
Publication date: April 2021
Connected Trials:
EMN09
Minimal Residual Disease Assessment by Multiparameter Flow Cytometry in Transplant-Eligible Myeloma in the EMN02/HOVON 95 MM Trial
Main author: Oliva
Publication date: April 2021
Connected Trials:
EMN02
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Main author: Ludwig
DOI: 10.1038/s41375-020-01016-0
Publication date: August 2020
Autologous Haematopoietic Stem-Cell Transplantation Versus Bortezomib-Melphalan-Prednisone, With or Without Bortezomib-Lenalidomide-Dexamethasone Consolidation Therapy, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (EMN02/HO95): A Multicentre, Randomised, Open-Label, Phase 3 Study
Main author: Cavo
DOI: 10.1016/S2352-3026(20)30099-5
Publication date: June 2020
Connected Trials:
EMN02
Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.
Main author: Cook
DOI: 10.1038/s41375-020-0918-6
Publication date: June 2020
Management of Patients With Multiple Myeloma in the Era of COVID-19 Pandemic: A Consensus Paper From the European Myeloma Network (EMN)
Main author: Terpos
DOI: 10.1038/s41375-020-0876-z
Publication date: May 2020
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
Main author: Terpos
DOI: https://doi.org/10.1038/s41375-020-0876-z
Publication date: May 2020
Time From First Symptom Onset to the Final Diagnosis of Multiple Myeloma (MM) – Possible Risks and Future Solutions: Retrospective and Prospective ‘Deutsche Studiengruppe MM’ (DSMM) and ‘European Myeloma Network’ (EMN) Analysis
Main author: Graziani
DOI: 10.1080/10428194.2019.1695051
Publication date: April 2020
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site, you agree to our use of cookies.OkPrivacy policy